Latest news
Braveheart charges past expectations with $382.5M IPO to fund cardio drug from Hengrui - Fierce BiotechFierce Biotech · Thu, 06 Aug 2026 12:27:37 GMTJiangsu Hengrui discloses 8.9% Kailera Therapeutics (KLRA) stake in ownership filing - Stock TitanStock Titan · Wed, 05 Aug 2026 10:05:24 GMTHengrui Pharmaceuticals Gets China Nod for Lung Cancer Combo Trials - MoomooMoomoo · Wed, 05 Aug 2026 03:25:12 GMTHengrui wins China approval for first domestically developed basal insulin analog - AllSciAllSci · Fri, 31 Jul 2026 12:56:19 GMTHow 2 FDA citations complicate Hengrui, Elevar’s push for liver cancer combo approval - Fierce PharmaFierce Pharma · Tue, 28 Jul 2026 07:00:00 GMTNomura Adjusts Jiangsu Hengrui Pharmaceuticals' Price Target to HK$82.18 From HK$87.49, Keeps at Buy - MoomooMoomoo · Mon, 27 Jul 2026 07:00:00 GMT